Testing a new treatment for lupus and rheumatoid arthritis

Plain-English translation of NCT06647069 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called /DR-0201 to see if it is safe and works for people with lupus or rheumatoid arthritis. Researchers want to find the best dose of this treatment and understand how it works in your body. If you join, you'll be in the study for about 13 months, taking the medication or receiving injections and having regular check-ups.

Many people with lupus and rheumatoid arthritis don't respond well enough to current treatments or can't tolerate them. This trial is exploring whether this new medication might offer a better option for patients whose disease remains active despite other therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with either systemic lupus erythematosus or rheumatoid arthritis (confirmed by your doctor using standard clinical criteria)
you have had moderate to severe disease activity that hasn't improved enough with at least one or two other medications over the past 12 weeks
you are an adult and willing to use effective birth control throughout the study and for 140 days after your last dose
you have specific blood test results (such as positive antibodies for lupus) that confirm your diagnosis
you are generally in stable health without severe organ involvement or complications that would make the study unsafe for you

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use contraception during the study
you have very severe disease features that could be harmed by the study medication
you have recently changed doses of steroid creams or other immune-suppressing skin treatments
you have active or untreated infections or other serious medical conditions that would make participation unsafe
you are unable to commit to the full 13-month study period including follow-up visits

What participation looks like

You'll visit the study clinic regularly over about 13 months. This includes an initial screening visit, a 71-day treatment period where you'll receive the medication (starting at a low dose that may increase), and follow-up visits for 42 weeks afterward to monitor how you're doing. You'll have blood tests to check your safety and how the medication is working, and your doctor will assess your disease activity at each visit. Some participants may continue with visits every 4 weeks after the main study ends until your immune cells return to normal levels.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Testing a new treatment for lupus and rheumatoid arthritis

What is this trial?

Do you qualify?

What participation looks like

Trial locations